New Haven Pharmaceuticals

company

About

New Haven Pharmaceuticals develops prescription pharmaceuticals that utilize drugs or GRAS active pharmaceutical ingredients.

  • 11 - 50

Details

Last Funding Type
Debt Financing
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company's novel product pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$25.17M
New Haven Pharmaceuticals has raised a total of $25.17M in funding over 2 rounds. Their latest funding was raised on Aug 17, 2016 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 17, 2016 Debt Financing $602.22K 1 Detail
Oct 7, 2015 Debt Financing $6.30M 1 Detail
Oct 23, 2014 Series B $11.78M 1 Detail
Dec 31, 2013 Debt Financing 1 Detail
Oct 29, 2012 Series A $6.49M 2 Detail

Investors

Number of Lead Investors
Number of Investors
3
New Haven Pharmaceuticals is funded by 3 investors. Advantage Capital and Horizon Technology Finance are the most recent investors.
Investor Name Lead Investor Funding Round
Advantage Capital Debt Financing
Horizon Technology Finance Debt Financing
EJ Funds Series B